on GENFIT (EPA:GNFT)
GENFIT Collaborates with EVerZom on Exosome-Based Therapy for Liver Failure
GENFIT has announced a new research collaboration with EVerZom to enhance its research in Acute-On-Chronic Liver Failure (ACLF) using exosome-based regenerative technology. This partnership aims to leverage EVerZom's expertise in exosome platforms, particularly their investigational drug candidate, EViv. EViv is developed to treat ACLF through innovative regenerative therapy methods.
Under the terms of the collaboration, GENFIT holds an exclusive option to license and advance EViv into clinical development, contingent on positive in vivo proof-of-concept results. This agreement combines EVerZom's advanced bioproduction capabilities with GENFIT's leadership in liver disease research, targeting rapid preclinical progress.
The collaboration marks a significant step towards novel therapeutic solutions for ACLF, utilizing exosomes, which are known for their stability and safety compared to traditional cell therapies.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENFIT news